Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Large Decrease in Short Interest

Fresenius SE & Co. (OTCMKTS:FSNUY) was the recipient of a large decrease in short interest in March. As of March 13th, there was short interest totaling 21,913 shares, a decrease of 66.5% from the February 26th total of 65,445 shares. Based on an average daily volume of 220,277 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company’s stock are short sold.

Wall Street Analyst Weigh In

A number of brokerages have commented on FSNUY. Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a research note on Monday, December 15th. Citigroup reiterated a “buy” rating on shares of Fresenius SE & Co. in a research note on Tuesday, February 3rd. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Fresenius SE & Co. presently has a consensus rating of “Buy”.

Fresenius SE & Co. Stock Down 1.2%

Shares of OTCMKTS FSNUY traded down $0.15 during trading on Friday, reaching $12.55. 35,052 shares of the stock were exchanged, compared to its average volume of 71,416. The company has a market capitalization of $28.27 billion, a price-to-earnings ratio of 19.92 and a beta of 0.75. The business’s 50-day moving average price is $14.25 and its 200 day moving average price is $14.39. The company has a quick ratio of 0.99, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Fresenius SE & Co. has a twelve month low of $9.78 and a twelve month high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.28 earnings per share for the quarter. Fresenius SE & Co. had a net margin of 5.71% and a return on equity of 10.38%. The business had revenue of $6.94 billion during the quarter. As a group, equities analysts forecast that Fresenius SE & Co. will post 0.79 EPS for the current fiscal year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.